Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.
Paolini, D., Rossoni, R., Guardione, D., Arena, V., Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer, <<VALUE IN HEALTH>>, 2015; 18 (7): 361-2-362. [doi:10.1016/j.jval.2015.09.701] [http://hdl.handle.net/10807/122889]
Economical and Organizational Impact of Adopting Different in Situ Hybridization Technologies to Assess HER2 Gene Amplification in Breast Cancer
Arena, VincenzoUltimo
Conceptualization
2015
Abstract
Human epidermal growth factor receptor 2 (HER2) status identification is established by immunohistochemistry and in situ hybridisation (ISH). Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in situ hybridization (FISH). Both methods are recommended by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. The primary aim of this analysis is to evaluate the economical and organizational impact by adopting FISH or SISH test for HER2 testing.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
